معرفی
Andrea Bertotti is a Professor in the Department of Oncology at the University of Turin, Italy. His research focuses on cancer biology, particularly receptor tyrosine kinase (RTK) signaling, oncogene addiction, and targeted therapies. He leads translational studies on metastatic colorectal cancer (CRC), leveraging patient-derived xenograft (PDX) models to predict clinical responses and investigate drug resistance mechanisms. Key contributions include identifying HER2 amplification as a predictive marker for anti-EGFR therapy resistance, now integrated into clinical guidelines.
His work emphasizes synthetic lethality strategies, tumor evolution, and drug tolerance. Bertotti coordinates a large PDX platform of over 800 CRC liver metastases, systematically profiled for molecular traits and drug responses. He explores evolutionary properties of tumors, including mutation rates under therapeutic pressure, using patient-derived tumoroids (PDTs) and cell lines. His ERC Consolidator Grant (N°724748) supports investigations into residual disease mechanisms post-EGFR therapy.
Academically, Bertotti teaches courses in Molecular Oncology and Precision Medicine. He serves on the Department Council and contributes to academic committees. His research bridges basic science and clinical translation, aiming to advance personalized cancer therapies.
